163 related articles for article (PubMed ID: 24810637)
1. Treatment with a fusion protein of the extracellular domains of NKG2D to IL-15 retards colon cancer growth in mice.
Xia Y; Chen B; Shao X; Xiao W; Qian L; Ding Y; Ji M; Gong W
J Immunother; 2014 Jun; 37(5):257-66. PubMed ID: 24810637
[TBL] [Abstract][Full Text] [Related]
2. Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells.
Chen Y; Chen B; Yang T; Xiao W; Qian L; Ding Y; Ji M; Ge X; Gong W
Cell Mol Immunol; 2017 Mar; 14(3):293-307. PubMed ID: 26364916
[TBL] [Abstract][Full Text] [Related]
3. Chitosan nanoparticle-based delivery of fused NKG2D-IL-21 gene suppresses colon cancer growth in mice.
Tan L; Han S; Ding S; Xiao W; Ding Y; Qian L; Wang C; Gong W
Int J Nanomedicine; 2017; 12():3095-3107. PubMed ID: 28450784
[TBL] [Abstract][Full Text] [Related]
4. Delivery of human NKG2D-IL-15 fusion gene by chitosan nanoparticles to enhance antitumor immunity.
Yan C; Jie L; Yongqi W; Weiming X; Juqun X; Yanbing D; Li Q; Xingyuan P; Mingchun J; Weijuan G
Biochem Biophys Res Commun; 2015 Jul; 463(3):336-43. PubMed ID: 26022121
[TBL] [Abstract][Full Text] [Related]
5. MULT1E/mIL-12: a novel bifunctional protein for natural killer cell activation.
Tietje A; Li J; Yu X; Wei Y
Gene Ther; 2014 May; 21(5):468-75. PubMed ID: 24572784
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy induced by human ovarian cancer cells secreting IL-21 alone or combination with GM-CSF cytokines in nude mice model.
Dou J; Wang Y; Wang J; Zhao F; Li Y; Cao M; Hu W; Hu K; He XF; Chu L; Jiang C; Gu N
Immunobiology; 2009; 214(6):483-92. PubMed ID: 19389515
[TBL] [Abstract][Full Text] [Related]
7. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma.
Wang T; Sun F; Xie W; Tang M; He H; Jia X; Tian X; Wang M; Zhang J
Cancer Lett; 2016 Mar; 372(2):166-78. PubMed ID: 26791237
[TBL] [Abstract][Full Text] [Related]
8. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
[TBL] [Abstract][Full Text] [Related]
9. An IL-12/Shh-C domain fusion protein-based IL-12 autocrine loop for sustained natural killer cell activation.
Zhu L; Zhao Z; Wei Y; Marcotte W; Wagner TE; Yu X
Int J Oncol; 2012 Aug; 41(2):661-9. PubMed ID: 22581115
[TBL] [Abstract][Full Text] [Related]
10. The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma.
Rothe A; Jachimowicz RD; Borchmann S; Madlener M; Keßler J; Reiners KS; Sauer M; Hansen HP; Ullrich RT; Chatterjee S; Borchmann P; Yazaki P; Koslowsky TC; Engert A; Heukamp LC; Hallek M; von Strandmann EP
Int J Cancer; 2014 Jun; 134(12):2829-40. PubMed ID: 24242212
[TBL] [Abstract][Full Text] [Related]
11. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response.
Cho HM; Rosenblatt JD; Tolba K; Shin SJ; Shin DS; Calfa C; Zhang Y; Shin SU
Cancer Res; 2010 Dec; 70(24):10121-30. PubMed ID: 21159634
[TBL] [Abstract][Full Text] [Related]
12. IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas.
Kim PS; Kwilas AR; Xu W; Alter S; Jeng EK; Wong HC; Schlom J; Hodge JW
Oncotarget; 2016 Mar; 7(13):16130-45. PubMed ID: 26910920
[TBL] [Abstract][Full Text] [Related]
13. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
[TBL] [Abstract][Full Text] [Related]
14. IL-7 inhibits tumor growth by promoting T cell-mediated antitumor immunity in Meth A model.
Tang JC; Shen GB; Wang SM; Wan YS; Wei YQ
Immunol Lett; 2014; 158(1-2):159-66. PubMed ID: 24406503
[TBL] [Abstract][Full Text] [Related]
15. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.
Basher F; Jeng EK; Wong H; Wu J
Oncotarget; 2016 Jan; 7(1):814-30. PubMed ID: 26625316
[TBL] [Abstract][Full Text] [Related]
16. MICA/IL-12: A novel bifunctional protein for killer cell activation.
Tietje A; Yang X; Yu X; Wei Y
Oncol Rep; 2017 Mar; 37(3):1889-1895. PubMed ID: 28098874
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
Zhang T; Sentman CL
Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
[TBL] [Abstract][Full Text] [Related]
18. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
Hervieu A; Rébé C; Végran F; Chalmin F; Bruchard M; Vabres P; Apetoh L; Ghiringhelli F; Mignot G
J Invest Dermatol; 2013 Feb; 133(2):499-508. PubMed ID: 22951720
[TBL] [Abstract][Full Text] [Related]
19. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
[TBL] [Abstract][Full Text] [Related]
20. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.
Peng LS; Penichet ML; Morrison SL
J Immunol; 1999 Jul; 163(1):250-8. PubMed ID: 10384123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
